An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new challenger to blockbusters from Novo Nordisk A/S and Eli Lilly & Co.

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

There is new guidance on the use of popular weight loss medications like Zepbound and Wegovy to help improve heart health.

Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Expect social and relationships to change after weight loss. The more weight you lose and the more you change your lifestyle ...

The race to develop muscle-preserving treatments alongside popular obesity drugs like Eli Lillys (NYSE:LLY) Zepbound and Novo ...

In adults with obesity and prediabetes, weight loss achieved with tirzepatide was sustained at more than 3 years, according ...

At a time when Novo Nordisk has appeared to be slipping behind rival Eli Lilly and its blockbuster Zepbound (tirzepatide) in ...

Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...